Monoclonal Anti-DXD&Exatecan Antibody, Mouse IgG1 (MALS verified)
抗體來源（Source）
Monoclonal Anti-DXD&Exatecan Antibody, Mouse IgG1 is recombinantly produced from human 293 cells (HEK293).
亞型（Isotype）
Mouse IgG1/kappa
特異性（Specificity）
Specifically recognizes the target-DXD.
應(yīng)用（Application）
PK, PD, Immunoassay and ELISA
純度（Purity）
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
內(nèi)毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景（Background）
Dxd (Exatecan ADC derivative) is a potent DNA topoisomerase I inhibitor with an IC50 of 0.31 uM for targeting ADCs (DS-8201A). Dxd was cytotoxic to human tumor cell lines KPL-4, NCI-N87 and SK-BR, 3 and the IC50s of MDA-MB-468 was 1.43 NM-4.07 nM, while lgGADC (Dxd as payload) had no inhibitory effect on HER2 expression in the 4 cell lines. DS8201a (Dxd as payload) had a significant inhibitory effect on HER2-positive KPL-4 and NCI cell lines N87 and SK-BRwith IC50 values of 26.8, 25.4 and 6.7 ng/mL, respectively, but had no inhibitory effect on MDA MB-468 (IC50, > 10000 - mL). HRP-anti-DXD-antibody is a conjugation product of HRP and anti-DXD-antibody. It can be used in PK, PD analysis and ELISA.
關(guān)鍵字： Anti DXD;DXD抗體;單克隆DXD抗體;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。